143 related articles for article (PubMed ID: 29692878)
1. Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.
Pyenson BS; Dieguez G; Ferro C; Mavinkurve M; Gonzalez YS
Am Health Drug Benefits; 2018 Feb; 11(1):30-37. PubMed ID: 29692878
[TBL] [Abstract][Full Text] [Related]
2. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
3. Actuarial analysis of private payer administrative claims data for women with endometriosis.
Mirkin D; Murphy-Barron C; Iwasaki K
J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization and cost in a commercially insured population with schizophrenia.
Fitch K; Iwasaki K; Villa KF
Am Health Drug Benefits; 2014 Jan; 7(1):18-26. PubMed ID: 24991388
[TBL] [Abstract][Full Text] [Related]
5. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of HIV in a Commercially Insured Population in the United States.
Chen CY; Donga P; Campbell AK; Taiwo B
J Health Econ Outcomes Res; 2023; 10(1):10-19. PubMed ID: 36721765
[No Abstract] [Full Text] [Related]
7. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
8. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
9. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.
Fitch K; Pyenson BS; Iwasaki K
J Manag Care Pharm; 2013 Oct; 19(8):609-20, 620a-620d. PubMed ID: 24074007
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
[No Abstract] [Full Text] [Related]
11. Factors Associated With Testing for Hepatitis C Infections Among a Commercially Insured Population of Persons With HIV, United States 2008-2016.
King H; Bull-Otterson L; Hoover KW; Huang HYA; Zhu W; Thompson W
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa222. PubMed ID: 32617381
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.
Ramsey SD; Unger JM; Baker LH; Little RF; Loomba R; Hwang JP; Chugh R; Konerman MA; Arnold K; Menter AR; Thomas E; Michels RM; Jorgensen CW; Burton GV; Bhadkamkar NA; Hershman DL
JAMA Oncol; 2019 Apr; 5(4):497-505. PubMed ID: 30653226
[TBL] [Abstract][Full Text] [Related]
13. Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population.
Mattingly TJ; Pandit NS; Onukwugha E
Infect Dis Ther; 2019 Jun; 8(2):219-228. PubMed ID: 30825134
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
16. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.
Goolsby Hunter A; Rosenblatt L; Patel C; Blauer-Peterson C; Anduze-Faris B
Curr Med Res Opin; 2017 May; 33(5):829-836. PubMed ID: 28128648
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Routine screening for hepatitis C viral infection in patients undergoing elective cranial neurosurgery.
Nussbaum ES; Kallmes K; Lowary J; Nussbaum LA
J Neurosurg; 2018 Sep; 131(3):941-948. PubMed ID: 30215562
[TBL] [Abstract][Full Text] [Related]
20. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
